The implementation of Tolnagro Ltd.’s project with identification number BAR-1.1.1-22-2022-00016, entitled “Technology Development at the Gumigyár Street Site of Tolnagro Ltd.” has been completed.

The implementation of Tolnagro Ltd.’s project with identification number BAR-1.1.1-22-2022-00016, entitled “Technology Development at the Gumigyár Street Site of Tolnagro Ltd.” has been completed.

Tolnagro Veterinary Ltd. was founded in 1996 in Szekszárd. The Tolnagro Group is a 100% Hungarian, family-owned company group with a history of 25 years. It is a key player in the Hungarian agricultural sector and the market leader in the wholesale of veterinary products. With the experience gained over the past 25 years, we strive to provide the highest level of service to our nearly 22,000 partners, offering a selection of more than 18,000 products through both our online and traditional (offline) platforms. The 100% Hungarian-owned family business had a turnover of HUF 25 billion in 2020.

The company’s main activities include the wholesale and retail of pharmaceuticals and medical products, as well as the trade of feed for livestock and companion animals. In addition to commercial activities, our own product manufacturing operations are also steadily strengthening, supplying our commercial units and thereby further expanding our pharmaceutical production activities (classified under 2120'25 Pharmaceutical Manufacturing).

Within the framework of the tender, the company implemented the following development from HUF 80,685,298. The key to the Tolnagro Group’s development and economic growth is the extent to which we can reduce our dependence on foreign suppliers and contract manufacturers. The clear solution was to use our own marketing authorizations, our in-house technological developments, and our trained specialists to produce our products in one place, with the highest quality and at the fastest pace. The aim of the development was to establish a modern veterinary pharmaceutical factory and laboratory in Budapest that meets the requirements of the 21st century.

Thanks to modern production technologies, the new facility not only improves the quality of our products but also significantly expands our product range, enabling the replacement of products currently imported from the United Kingdom. This eliminates dependence on foreign suppliers and mitigates the negative impacts of Brexit. As a result of our research and development activities, our existing portfolio could be expanded by an additional 100–150 products. Moreover, this development not only reduces import difficulties for the group’s companies but also creates manufacturing capacities that enable other domestic market players to replace their current dependence on the United Kingdom with Hungarian production, thus overcoming Brexit-related supply difficulties.

The detailed technical and financial content of the development was designed to fully comply with GMP pharmaceutical manufacturing requirements, creating an automated and highly digitalized system.

The technology development extended to several areas covering both production and related supplementary fields (such as the wastewater treatment system). During the development, technological equipment and tools were procured. The company purchased equipment for the manufacture of veterinary pharmaceuticals and for water treatment arising from the production process. To expand manufacturing capacities, a colloid mill system and a purified water production system were also acquired.